Aurobindo Pharma Subsidiary Apitoria Unit-II Receives US FDA EIR with VAI Classification
Aurobindo Pharma Ltd 路 Others (Uncategorized) 路 11 Nov 2026, 5:04 pm
Aurobindo Pharma Subsidiary Apitoria Unit-II Receives US FDA EIR with VAI Classification Aurobindo Pharma鈥檚 wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) from the US FDA for its Unit-II API manufacturing facility at Gaddapotharam, Telangana. The regulatory agency classified the facility as "Voluntary Action Indicated" (VAI) following its inspection conducted between 7th Sep'26 and 15th Sep'26. The US FDA has officially concluded that the inspection is closed under 21 CFR 20.64(d)(3), clearing regulatory overhang for the manufacturing unit.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
- Approved the proposal of Merger of two wholly owned subsidiaries of the Company. 路 05 Nov 2026
